Absence of aromatase protein and mRNA expression in endometriosis

S. Colette1, J.C. Lousse1, S. Defrère1, M. Curaba1, J.F. Heilier2, A. Van Langendonckt1, M. Mestdagh3, J.M. Foidart3, E. Loumaye4, and J. Donnez1,5

1Université Catholique de Louvain, Faculty of Medicine, Gynecology Unit, 1200 Brussels, Belgium
2Université Catholique de Louvain, Faculty of Medicine, Industrial Toxicology and Occupational Medicine Unit, 1200 Brussels, Belgium
3Université de Liège, Laboratory of Tumor and Development Biology, 4000 Liège, Belgium
4PregLem S.A, 1228 Plan-les Ouates, Geneva, Switzerland
5Correspondence address. Tel: +32-2-764-95-01; Fax: +32-2-764-95-07; E-mail: jacques.donnez@uclouvain.be/anne.lepage@uclouvain.be

BACKGROUND: Aromatase has been reported to be involved in estrogen biosynthesis and expressed in eutopic and ectopic endometrium of endometriosis patients. The objective of the present study was to investigate its expression and localization in three distinct types of endometriosis.

METHODS: Human peritoneal, ovarian and rectovaginal endometriotic lesions and matched eutopic endometrium were collected from patients during laparoscopy. Aromatase protein localization (immunohistochemistry, n = 63) and mRNA expression [quantitative polymerase chain reaction (Q-PCR), n = 64] were assessed.

RESULTS: No aromatase protein was detected by immunohistochemistry in either the glandular or stromal compartment of endometriotic lesions or eutopic endometrium, while it was strong in placental syncytiotrophoblasts, granulosa and internal theca cells from pre-ovulatory follicles, and luteal cells from corpus luteum. By Q-PCR, low but discernible levels of aromatase expression were found in endometriomas, probably due to follicular expression. Transcripts for aromatase were barely detectable in only a few peritoneal and rectovaginal endometriotic lesions, and a few eutopic endometrium samples, probably due to contaminating surrounding tissues (adipose tissue, intact peritoneum).

CONCLUSIONS: Unlike previous studies, we observed no aromatase protein in any of the endometriosis types, and barely detectable aromatase mRNA expression, suggesting that locally produced aromatase (within endometriotic lesions) may be less implicated in endometriosis development than previously postulated. Potential factors responsible for these discrepancies are discussed.

Key words: aromatase / peritoneal endometriosis / ovarian endometriosis / rectovaginal endometriosis

Introduction

Endometriosis is one of the most commonly encountered benign gynecological disorders, characterized by the proliferation of endometrial glands and stroma outside the uterine cavity. The prevalence of endometriosis varies considerably from study to study. Approximately 10–15% of reproductive-age women are affected, but this figure rises to 40% of women presenting with infertility (Donnez et al., 2002). We have identified three types of endometriosis, each with a different pathogenesis: peritoneal, ovarian and rectovaginal (Nisolle and Donnez, 1997).

The origin and establishment of peritoneal endometriosis can be explained by the ability of endometrial cells to survive, adhere, invade tissues and proliferate outside their eutopic location, according to Sampson’s implantation theory (Sampson, 1927; Nisolle and Donnez, 1997). In case of ovarian endometriosis, the presence of mesothelial invagination in continuum with endometriotic tissue suggests a metaplastic histogenesis of ovarian endometriotic lesions, but endometriotic cysts may also originate from invagination of superficial endometriotic implants. For rectovaginal nodules, immunocytochemical results show poor differentiation and hormonal independence of these lesions, and point to a close relationship with their mesodermal Müllerian origin (Nisolle and Donnez, 1997).

Endometriosis develops mostly in women of reproductive age and regresses after menopause or ovariectomy, clearly implicating estrogen in the establishment and maintenance of this disease. Most pharmacotherapeutic strategies against endometriosis are therefore designed to generate a low-estrogen milieu (Mihalyi et al., 2006).
Aromatase is a key enzyme synthesizing estrogens from androgens, being involved in the conversion of androstenedione and testosterone to estrone and estradiol (E₂), respectively. Only one single gene (CYP19) encodes aromatase in mice and humans. In a number of species, including humans, aromatase expression shows broad tissue distribution and is found in the placenta, gonads, brain, adipose tissue and bone (Simpson et al., 1994). This enzyme is localized in the endoplasmic reticulum of estrogen-producing cells (Bulun et al., 2001; Simpson et al., 2001). Aromatase expression is essential for reproductive development and fertility, and aberrant aromatase expression in tissues is associated with a number of pathological conditions, including gynecomastia and sexual precocity, tumors of the breast, testes, liver, adrenal cortex and uterus, and endometriosis (Conley and Hinshelwood, 2001).

Aromatase expression in endometriosis has now been confirmed in numerous reports at the transcriptional level (Noble et al., 1996; Dheenadayalu et al., 2002; Ishihara et al., 2003; Heilier et al., 2006a; b; Matsuzaki et al., 2006; Bukulmez et al., 2007; Dassen et al., 2007; Kyama et al., 2007; Smuc et al., 2007; Attar et al., 2008; Smuc et al., 2008), activity level (Kitawaki et al., 1997; Noble et al., 1997; Murakami et al., 2006; Purohit et al., 2007) and protein level (Kitawaki et al., 1997, 1999a, b; Ishihara et al., 2003; Wößler et al., 2005; Murakami et al., 2006; Velasco et al., 2006; Acien et al., 2007; Bukulmez et al., 2007; Hudelist et al., 2007). However, there is no consensus on its localization, since some authors found aromatase protein in stromal components (Fazleabas et al., 2003; Wößler et al., 2005; Velasco et al., 2006; Acien et al., 2007), while others demonstrated glandular localization (Kitawaki et al., 1997, 1999a, b; Ishihara et al., 2003; Wößler et al., 2005; Matsuzaki et al., 2006; Fechner et al., 2007; Hudelist et al., 2007).

In addition, the extent of aromatase mRNA expression in endometriotic tissue is controversial, with published papers showing widely varying values (from barely detectable levels to a 530-fold increase!) (Heilier et al., 2006b; Bukulmez et al., 2007; Dassen et al., 2007; Kyama et al., 2007; Smuc et al., 2007; Aghajanova et al., 2009). Moreover, Delvoux et al. (2008) recently showed a complete absence of aromatase activity in endometriotic samples.

Aromatase inhibitors (AIs) have been successfully developed and one of their main therapeutic indications is hormone-dependent breast cancer (Fabian, 2007). Case reports and pilot studies have suggested that AIs combined with progestogens or oral contraceptives may effectively reduce pain symptoms related to the presence of endometriosis (presenting for reanastomosis or tubal sterilization) using an endometrial biopsy curette (mean age of patients: 38.0 ± 6.1 years; proliferative phase: 3; secretory phase: 7; all in spontaneous cycles). For 63 of the 127 patients, biopsies were fixed in 4% formaldehyde, embedded in paraffin and serially sectioned (5 µm) for immunohistochemical study. For the remaining 64 patients, fragments of biopsies were frozen in liquid nitrogen and kept at −80°C until mRNA analysis.

All the biopsies were dissected by an expert gynecologist. Histological examination of the excised tissue was systematically carried out after hematoxylin–eosin staining, and the nature of the lesions was histologically confirmed in all cases (presence of glands and stroma).

### Immunohistochemical analysis

**Presellection of anti-human aromatase antibody**

The specificity of four anti-human aromatase antibodies, used in previous endometriosis studies (Fazleabas et al., 2003; Bukulmez et al., 2007; Fechner et al., 2007), was evaluated by western blot on placental protein extracts [1/250; horseradish peroxidase (HRP)-conjugated goat anti-mouse secondary antibodies. 1/10 000; 40 µg of protein charged in each lane]

Two rabbit polyclonal antibodies (BioVision Research Products, Mountain View, CA, USA; Abcam, Cambridge, UK) were excluded, as their specificity could not be confirmed. Indeed, a second band was observed in our protein extracts at 35 kDa. Sequencing (Eurogentec S.A., Seraing, Belgium) of this band showed that it was not due to degradation products, as hypothesized on the BioVision data sheet (data not shown).

Two mouse monoclonal anti-human aromatase antibodies (Acris Antibodies, Hidenhausen, Germany (here denoted AbI); and AbD Serotec, Oxford, UK (here denoted AbII)) were shown to be specific, since only one band (around 55 kDa) was detected. This band was sequenced (Eurogentec S.A.) and was shown to correspond to aromatase (data not shown). They were developed in 2002 (Turner et al., 2002) and are directed against a conserved epitope of aromatase corresponding to amino acids 376–390 of the human aromatase sequence (KALEDDVID-GYPVKK, sequence compared with the aromatase sequence stored in the GenPept database: nP_000094). It was therefore decided to use only monoclonal antibodies in this study.

**Aromatase immunohistochemistry**

Tissue sections were deparaffinized in Histofast (YYSOLAB S.A., Beesse, Belgium), hydrated in isopropanol (Merck, Darmstadt, Germany), washed briefly in water and incubated in hydrogen peroxide (Merck) 3% v/v in methanol (Merck) for 30 min to block endogenous peroxidase activity. Slides were rinsed in water and heat epitope retrieval was performed using Target Retrieval Solution, pH 9.0 (Dako, ViaReal Carpinteria CA, USA)+0.1% Tween 20 (Sigma-Aldrich, Steinheim, Germany) for 20 min at 96°C. Sections were rinsed in phosphate-buffered saline (PBS)/TWEEN 20 and non-specific reactions were blocked using bovine serum albumin (BSA) 5% (Sigma-Aldrich)+non-fat dry milk 2% (BioRad, Hercules, CA, USA) in hypertensive Tris buffer (pH 7.4) for 1 h at room temperature (RT). Endogenous biotin blocking was performed using the

### Materials and Methods

The use of human tissue for this study was approved by the Institutional Review Board of the Université Catholique de Louvain.

**Biopsy collection**

Biopsies of endometriotic lesions and their matched eutopic endometrium were taken from 127 patients undergoing laparoscopy (mean age of patients: 31.8 ± 6.3 years). In 71 cases, patients were in ovulatory cycles and biopsies were dated as proliferative (n = 35) or secretory (n = 36). In 56 cases, patients were undergoing hormonal therapy (47 estroprogestin treatment and 9 GnRH analog therapy). Biopsies were classified as peritoneal (n = 64), ovarian (n = 66) or rectovaginal (n = 65) endometriotic lesions.

Eutopic endometrium was also collected from 10 patients without endometriosis (presenting for reanastomosis or tubal sterilization) using an endometrial biopsy curette (mean age of patients: 38.0 ± 6.1 years; proliferative phase: 3; secretory phase: 7; all in spontaneous cycles).

For 63 of the 127 patients, biopsies were fixed in 4% formaldehyde, embedded in paraffin and serially sectioned (5 µm) for immunohistochemical study. For the remaining 64 patients, fragments of biopsies were frozen in liquid nitrogen and kept at −80°C until mRNA analysis.

All the biopsies were dissected by an expert gynecologist. Histological examination of the excised tissue was systematically carried out after hematoxylin–eosin staining, and the nature of the lesions was histologically confirmed in all cases (presence of glands and stroma).
Biotin Blocking System (Dako) as follows: avidin solution was incubated for 10 min at RT and sections were rinsed in PBS/Tween 20. Thereafter, biotin solution was incubated for 10 min at RT and sections were washed in PBS/Tween 20. Sections were incubated with anti-aromatase antibodies diluted 1:50 (AbI and AbII) in BSA 2.5%-non-fat dry milk 1% in hypersaline Tris buffer (pH 7.4) overnight at 4°C. Biotinylated rabbit anti-mouse secondary antibodies (Dako) were then diluted 1:100 in BSA 2.5%-non-fat dry milk 1% in hypersaline Tris buffer (pH 7.4) and incubated with the tissue sections for 30 min at RT. Bound antibodies were visualized by incubating the sections with avidin–biotin complex/HRP (ABC/HRP) reagent (Vector Laboratories, Inc., Burlingame, CA, USA) for 15 min at RT, followed by incubation with 3,3'-diaminobenzidine (Dako) for a further 15 min at RT. Sections were finally counterstained with Mayer’s hemalum solution (Merck).

Human placental and ovarian tissues were utilized as positive controls for aromatase expression (Turner et al., 2002). Negative control sections were processed using non-specific IgG, or omitting the specific primary antibodies.

Staining of iron deposits
Ferric iron deposits were evidenced in ovarian endometriotic lesions using Perls’ Prussian blue staining (Perls, 1867). Briefly, dewaxed 5 μm-thick lesion sections were stained for 20 min in a solution of 1% kalium hexacyanoferrate and 2% (v/v) hydrochloric acid and nuclei were counterstained with nuclear fast red.

PCr and Q-PCR studies
Samples were homogenized in TRizol reagent (Life Technologies, Gaithersburg, MD, USA) using an Ultra-Turrax T25 homogenizer (Janke and Kunkel, Brussels, Belgium). RNA quality was checked by spectrophotometry and analysis of the 28S/18S ratio after agarose gel electrophoresis. Total RNA was isolated using the classic chloroform extraction and isopropanol precipitation method. Total RNA (2.5 μg) was reverse transcribed with random hexamers (Eurogentec S.A.) and SuperScript RT RNase H2 reverse transcriptase (Life Technologies).

The specificity of the primary antibodies was tested by western blotting. Only one band (~55 kDa) corresponding to aromatase was detected in human placental protein extracts with AbI (Fig. 1A, lane I) and AblI. In a preliminary experiment conducted in our laboratory, only one band was observed in mature testicular protein samples too (data not shown).

Aromatase immunohistochemistry set-up
The specificity of the primary antibodies was tested by western blotting. Only one band (~55 kDa) corresponding to aromatase was detected in human placental protein extracts with AbI (Fig. 1A, lane I). Biotinylated rabbit anti-mouse antibodies diluted 1:50 (AbI and AbII), their matched eutopic endometrium (48 with AbI; 63 with AbII) and human placental and ovarian tissues were utilized as positive controls (Fechner et al., 2003; Ishihara et al., 2003; Velasco et al., 2006; Acien et al., 2007; Bukulmez et al., 2007; Fechner et al., 2007; Dudelstein et al., 2007). However, endogenous biotin was labeled in the epithelial lining of endometriotic glands incubated with (Fig. 1B) or without (Fig. 1C) primary antibody (AbI and AbII). An endogenous biotin blocking step was therefore added before incubation with primary antibody, which led to the loss of glandular staining.

Aromatase protein localization (immunohistochemistry) in endometriotic lesions
As observed in previous studies, placental syncytiotrophoblasts (Fig. 1D), granulosa and internal theca cells of pre-ovulatory follicles (Fig. 1E and F), and luteal cells of corpus luteum (Fig. 1G) were found to stain positive for aromatase. All endometriotic lesions (19 peritoneal, 19 ovarian and 20 rectovaginal with AblI; 34 peritoneal, 34 ovarian and 30 rectovaginal with AbII), their matched eutopic endometrium (48 with AblI; 63 with AbII), and endometrium from disease-free patients (n = 10) were found to be aromatase-negative in both the glandular and stromal compartments (Table I, Fig. 2A–D).

Results
In this study, aromatase expression was investigated in three distinct endometriotic entities (peritoneal, ovarian and rectovaginal endometriotic lesions) and their matched endometrium. The histological characteristics of endometriosis were always confirmed after hematoxylin–eosin staining by an experienced pathologist.

Aromatase immunohistochemistry was performed on paraffin-embedded tissue using the avidin–biotin amplification system, as applied in previous studies (Kitawaki et al., 1997; Turner et al., 2002; Fazleabas et al., 2003; Ishihara et al., 2003; Velasco et al., 2006; Acien et al., 2007; Bukulmez et al., 2007; Fechner et al., 2007; Dudelstein et al., 2007). However, endogenous biotin was labeled in the epithelial lining of endometriotic glands incubated with (Fig. 1B) or without (Fig. 1C) primary antibody (AbI and AbII). An endogenous biotin blocking step was therefore added before incubation with primary antibody, which led to the loss of glandular staining.
As expected, on endometrioma sections, granulosa cells and internal theca cells from pre-ovulatory follicles were shown to be aromatase-positive. Non-specific stromal staining was also observed on these sections (Fig. 2E). This was due to iron deposition, as assessed by an experienced pathologist and confirmed by Perls’ staining (Fig. 2F).

Preliminary results obtained by western blot with AbI and AbII on protein extracted from endometriotic lesions and their matched eutopic endometrium (10 peritoneal lesions, 8 ovarian lesions, 8 rectovaginal lesions, 8 eutopic endometrium; mean age of patients: 28.4 ± 5.4 years; proliferative phase: 7; secretory phase: 5; spontaneous cycles: 5; estroprogestin treatment: 7; GnRH analog therapy: 1) showed an absence of aromatase protein in these samples (Fig. 1A, lanes 2–9), confirming the immunohistochemical results.

**Aromatase gene expression (PCR and Q-PCR) in endometriotic lesions**

An initial PCR study (35 cycles) was conducted with a first set of primers (Fig. 3A). Although a band was detected in placental mRNA extracts, no aromatase expression was observed in endometriotic lesions (8 peritoneal, 8 ovarian and 8 rectovaginal) or matched eutopic endometrium (n = 15) (Table II).

Q-PCR analysis (increased to 40 cycles) was therefore performed on mRNA extracted from other endometriotic lesions (11 peritoneal, 11 ovarian and 17 rectovaginal) and their matched eutopic endometrium.
endometrium \( (n = 30) \), with other sets of primers (Fig. 3B). Discernible levels (near the detection limit) were found in almost all the endometriomas tested \((10/11; \text{mean aromatase } C_T: 35.0 \pm 1.9; \text{mean GAPDH } C_T: 20.4 \pm 1.2)\), in a few samples of peritoneal \((1/11)\) and rectovaginal \((3/17)\) endometriotic lesions, and in one sample of eutopic endometrium \((1/30)\) (Table II).
A third analysis was conducted with TaqMan probes (Fig. 3C). Again, discernible levels were found in almost all the endometriomas tested (10/13; mean aromatase Ct: 34.6 ± 2.0; mean cyclophilin A Ct: 25.5 ± 0.6), in a few samples of peritoneal endometriotic lesions (4/11), and in one sample of eutopic endometrium (1/17). No aromatase expression was detected in rectovaginal endometriotic lesions (Table II).

Plasmids were constructed and Q-PCR was applied to determine the limit of detection (according to the procedure described on the Applied Biosystems website: http://www3.appliedbiosystems.com/cms/groups/mcb_marketing/documents/generaldocuments/cms_042486.pdf). This corresponds to the Ct value of samples containing 10 molecules of mRNA of genes of interest (aromatase SYBR Green: 38.0; GAPDH SYBR Green: 38.1; aromatase TaqMan: 37.6; cyclophilin A TaqMan: 38.2).

**Discussion**

In endometriosis, aromatase is thought to be involved in a positive feedback loop that favors expression of key steroidogenic genes (Bulun et al., 2005). According to this hypothesis, estrogen stimulates production of the cyclooxygenase type 2 (COX-2) enzyme, resulting in elevated levels of prostaglandin E2 (PGE2), which is a potent stimulator of aromatase activity in endometriosis. This leads to continuous local production of E2 and PGE2 in endometriotic tissue. Estrogen enhances the growth and invasion of endometriotic tissue, while...
prostaglandins mediate pain, inflammation and infertility (Bulun et al., 2005). This molecular link between inflammation and estrogen production could be responsible in part for the devastating symptoms of endometriosis.

The main objective of this study was to precisely localize (stromal and/or glandular tissue) and quantify aromatase expression in three distinct types of endometriotic lesions (peritoneal, ovarian and recto-vaginal) by immunohistochemistry and Q-PCR. No aromatase protein was detected in the glands or stroma of any lesions by immunohistochemistry, while Q-PCR revealed only low aromatase mRNA levels in endometriomas, and barely detectable levels in a few peritoneal and recto-vaginal endometriotic lesions and eutopic endometrium samples.

Our method of immunostaining was validated by several positive control tissues. Indeed, aromatase staining was found in human placental syncytiotrophoblasts, granulosa and internal theca cells of pre-ovulatory follicles, and luteal cells from corpus luteum. Similarly, pre-ovulatory follicles sometimes observed on endometrioma sections showed positive aromatase staining.

The specificity of anti-human aromatase antibodies was confirmed by western blot on human placental protein extracts, since a band corresponding to aromatase (~55 kDa) was detected with Ab1 and Ab1b, while a complete absence of bands was observed in endometriotic lesion protein extracts, confirming our immunohistochemical results.

Our study showed low levels of aromatase mRNA expression in ovarian endometriotic lesions, as observed in our previous studies (Heilier et al., 2006a, b). This was probably due to the presence of follicular cells in the biopsies. Indeed, follicles are known to have high aromatase levels before ovulation (Sasano et al., 1989), which was also evidenced in our immunohistochemical results.

The findings of the present study contradict most of the existing literature on the subject. Indeed, in published studies, aromatase was detected by immunohistochemistry (Kitawaki et al., 1997, 1999a, b; Ishihara et al., 2003; Wölfler et al., 2005; Velasco et al., 2006; Acien et al., 2007) and lesions induced in baboons (Fazleabas et al., 2003), while others demonstrate glandular aromatase localization in human endometriotic lesions (Kitawaki et al., 1997, 1999a, b; Ishihara et al., 2003; Wölfler et al., 2005; Hudelist et al., 2007) and lesions induced in mice (Fechner et al., 2007). Glandular aromatase expression was also evidenced by laser capture microdissection in human endometriotic lesions (Matsuzaki et al., 2006). However, a recent paper reported an absence of aromatase activity in endometriotic samples (Delvoux et al., 2008).

In our immunohistochemical analysis, glandular staining was based on avidin–biotin amplification, as in most papers showing aromatase protein localization in endometriosis (Turner et al., 2002; Fazleabas et al., 2003; Velasco et al., 2006; Acien et al., 2007; Fechner et al., 2007; Hudelist et al., 2007). Since we also detected labeling in our negative controls (endometriotic lesions without primary antibody), we added an endogenous biotin blocking step to our protocol before incubation with primary antibody (only previously done by Turner et al., 2002). This resulted in the disappearance of glandular staining. We therefore suggest that what some authors took to be aromatase protein in endometriotic lesions was actually endogenous biotin.

Moreover, similar staining to that found by other authors in human endometriotic lesions (Velasco et al., 2006; Acien et al., 2007) and induced endometriotic lesions in baboons (Fazleabas et al., 2003) was observed on our endometrioma sections. These authors considered this staining to be evidence of stromal localization of aromatase. However, on our sections, the presence of siderophages or iron deposits was suspected and subsequently confirmed by Perls’ staining. Indeed, the same surface areas were labeled with both stains.

Concerning PCR detection, Heilier et al. previously showed aromatase expression to be higher in endometriomas than in peritoneal and recto-vaginal endometriotic lesions (Heilier et al., 2006a, b). However, the majority of results were obtained after 40 cycles of amplification (up to 55 cycles) and the Ct values could well have resulted from

<table>
<thead>
<tr>
<th>Table II Summary of PCR and Q-PCR studies</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
<tr>
<td>Spontaneous</td>
</tr>
<tr>
<td>Proliferative</td>
</tr>
<tr>
<td>Protocol I: Peritoneal endometriosis</td>
</tr>
<tr>
<td>Ovarian endometriosis</td>
</tr>
<tr>
<td>Rectovaginal endometriosis</td>
</tr>
<tr>
<td>Eutopic endometrium</td>
</tr>
<tr>
<td>Protocol II: Peritoneal endometriosis</td>
</tr>
<tr>
<td>Ovarian endometriosis</td>
</tr>
<tr>
<td>Rectovaginal endometriosis</td>
</tr>
<tr>
<td>Eutopic endometrium</td>
</tr>
<tr>
<td>Protocol III: Peritoneal endometriosis</td>
</tr>
<tr>
<td>Ovarian endometriosis</td>
</tr>
<tr>
<td>Rectovaginal endometriosis</td>
</tr>
<tr>
<td>Eutopic endometrium</td>
</tr>
</tbody>
</table>
non-specific amplification. We therefore conducted new Q-PCR analysis with the same primers, but stopping mRNA amplification at 40 cycles, and included additional controls (analysis of mRNA quality, sequencing of amplification products, standard curve analysis with dilutions of plasmid constructions and limit of detection determination). We then checked the dissociation curves (only one peak observed for each sample) and Q-PCR efficiency (always higher than 0.98). The amplicon amplified with this protocol (protocol II) was also sequenced and confirmed. Nevertheless, we only detected low levels of aromatase in our endometrioma samples. As confirmed by our immunohistochemical results, these low levels were probably due to follicular cells contaminating the biopsies. Barely detectable levels of aromatase were also found in a few peritoneal and rectovaginal endometriotic lesions, and in some eutopic endometrium samples. Although the lesions were carefully dissected, one cannot exclude contamination by surrounding tissues, such as adipose tissue or intact peritoneum (Simpson et al., 1994; Kyama et al., 2007), which may account for the occurrence of a few aromatase mRNA copies in these samples.

Our study investigated a broad range of patients (in proliferative or secretory phases, treated with estroprogestins or GnRH analogs), and low levels of aromatase expression detected by Q-PCR were found in non-treated as well as treated patients, indicating that treatment and cycle phase had no impact on our results.

The present study, showing an absence of aromatase expression at both the protein and mRNA levels, is furthermore corroborated by a recent publication by Delvoux et al., who used a different technique but obtained similar results. Indeed, they were also unable to detect aromatase activity in their endometriotic samples (Delvoux et al., 2008).

The good results obtained with AIs in clinical trials for endometriosis treatment should therefore be reinterpreted in the light of our data. The beneficial effects of AIs may well be explained by a systemic response or by inhibition of estrogen production in intraperitoneal tissues, such as intact peritoneum (Kyama et al., 2007) or adipose tissue, rather than inhibition in endometriotic lesions themselves (Bulun et al., 2005). Although aromatase levels per adipose tissue fibroblast or peritoneal cell may be small, the sum of estrogen arising from all these cells in the peritoneal cavity could have an impact on endometriotic lesion development.

In conclusion, our results failed to confirm previously published studies on aromatase expression in human endometriotic lesions. Indeed, we observed no aromatase protein in the glandular or stromal compartments of ectopic endometrial tissue, and barely detectable aromatase mRNA expression, suggesting that locally produced aromatase (within endometriotic lesions) could be less implicated than previously postulated.

Acknowledgements

J.C.L. is an FNRS Research Fellow. The authors thank Dolores Gonzalez and Olivier Van Kerk (Department of Gynecology) for their technical assistance. We thank Mira Hryniuk, B.A., for reviewing the English language of the manuscript. We also thank the Department of Anatomopathology for endometriotic lesion embedding and hematoxylin–eosin staining, and especially Professor E. Marbaix for his interpretation of the immunohistochemical results.

Funding

Fonds de la Recherche Scientifique—FNRS, Belgium (no 1.5.130.08); Région Wallonne; PregLem S.A.; Vicomte Ph. de Spoelberch and Baron A. Frère.

References

Aromatase in human endometriotic lesions


Submitted on January 28, 2009; resubmitted on April 1, 2009; accepted on May 6, 2009.